Insider Buying: Pulse Biosciences (NASDAQ:PLSE) CEO Purchases $295,350.00 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) CEO Paul Laviolette purchased 15,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at approximately $295,350. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pulse Biosciences Price Performance

Shares of NASDAQ:PLSE opened at $23.96 on Thursday. The firm has a market capitalization of $1.63 billion, a PE ratio of -21.78 and a beta of 1.63. The firm’s 50-day moving average is $21.03 and its two-hundred day moving average is $17.69. Pulse Biosciences, Inc has a 1 year low of $12.56 and a 1 year high of $26.30.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.25 million. Analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its position in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after acquiring an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares during the last quarter. KLP Kapitalforvaltning AS boosted its stake in shares of Pulse Biosciences by 136.0% during the third quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after acquiring an additional 3,400 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the second quarter valued at $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

PLSE has been the subject of a number of research analyst reports. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 20th. Finally, Mizuho set a $30.00 price objective on Pulse Biosciences in a report on Friday, February 6th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences has a consensus rating of “Hold” and a consensus price target of $30.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.